Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YJ1b
- Development stage
- Unknown
- Lead developer
- Tianjin University
01
Overview
YJ1b: sourced facts only. name: "YJ1b, designed based on our previous finding, shown strong binding affinity toward CRBN (IC50 =0.206 μM) by forming a salt bridge interaction with amino acid residue Glu377 of CRBN, it was 13-fold compared with that of lenalidomide (IC50 =2.694 μM) in TR-FRET assay." [PMID:36750890]; target: "YJ1b, designed based on our previous finding, shown strong binding affinity toward CRBN (IC50 =0.206 μM) by forming a salt bridge interaction with amino acid residue Glu377 of CRBN, it was 13-fold compared with that of lenalidomide (IC50 =2.694 μM) in TR-FRET assay." [PMID:36750890]; developer: "School of Chemical Engineering and Technology, Tianjin University, Tianjin, 300072, P. R. China." [PMID:36750890]
02
Targets
CRBN (Cereblon)
Beyond the preview
Go deeper on YJ1b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YJ1b.